Trial of Erlotinib, Gemcitabine and Cisplatin in Metastatic Pancreatic Cancer

Sponsor
Gyeongsang National University Hospital
Study ID
NCT00922896
Phase
PHASE2
Status
Completed

Conditions

  • Metastatic Pancreatic Cancer

Eligibility Criteria

Sex
ALL
Age
18 Years - 70 Years
Healthy Volunteers
Not accepted

Interventions

  • Gemcitabine, Cisplatin, Erlotinib (Tarceva) — DRUG
    * Erlotinib 100 mg po q d daily AND * Gemcitabine 1000 mg/m² with 250 mL of normal saline intravenously infusion over 30 mins on Day 1, 8 * Cisplatin 25 mg/m2 with 150 mL of normal saline intravenously infusion over 60 mins on D1,8 Every 3 weeks

Study Details

The purpose of this study is to determine the response rate of gemcitabine, cisplatin and erlotinib in metastatic pancreatic cancer.

Key Dates

First listed
Jun 17, 2009
Start date
Jun 30, 2009
Status verified
Nov 2012
Primary completion
Aug 31, 2010
Completion
May 31, 2011

Study Design

Enrollment
22 participants (actual)
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT

Arms

  • Experimental: GPE
    Gemcitabine-Cisplatin-Erlotinib

Primary Outcome Measure

To assess the response rate associated with gemcitabine, erlotinib and cisplatin in patients with advanced pancreatic cancer [ Time Frame: Clinically assessed every cycle (month) and radiologically assessed every 2 cycles (6 weeks) with CT scan ]

Related Studies